Progression-free survival (PFS) and overall survival (OS) across ethnicities for patients with metastatic renal cell carcinoma (mRCC) receiving targeted therapies (TT) as first-line (1L) treatment

被引：0
|
作者：
Salgia, Nicholas [1 ]
Dizman, Nazli [1 ]
Bergerot, Paulo Gustavo [1 ]
Bergerot, Cristiane Decat [1 ]
Hsu, Joann [1 ]
Pal, Sumanta K. [1 ]
机构：
[1] City Hope Comprehens Canc Ctr, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
645
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC)
    Verzoni, Elena
    Iacovelli, Roberto
    Rizzo, Mimma
    Felici, Alessandra
    Cascinu, Stefano
    Di Lorenzo, Giuseppe
    Cerbone, Linda
    Ortega, Cinzia
    Masini, Cristina
    Giganti, Maria Olga
    Lorusso, Vito
    Messina, Caterina
    Atzori, Francesco
    De Vincenzo, Fabio
    Sacco, Cosimo
    Boccardo, Francesco
    Valduga, Francesco
    Massari, Francesco
    Tassi, Renato
    Procopio, Giuseppe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [2] Progression-free survival (PFS) of first-line VEGF-targeted therapy as a prognostic parameter for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
    Seidel, C.
    Fenner, M.
    Reuter, C. W.
    Ganser, A.
    Gruenwald, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS RECEIVING 3 TARGETED THERAPIES (TTS) FOR METASTATIC RENAL-CELL CARCINOMA (MRCC)
    Iacovelli, R.
    Santoni, M.
    Di Lorenzo, G.
    Cerbone, L.
    Aglietta, M.
    Masini, C.
    Giganti, M. O.
    Messina, C.
    Sternberg, C. N.
    Procopio, G.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 270 - 271
  • [4] Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal-cell carcinoma (mRCC)
    Elena, V.
    Iacovelli, R.
    Santoni, M.
    Di Lorenzo, G.
    Cerbone, L.
    Ortega, C.
    Masini, C.
    Giganti, M. O.
    Messina, C.
    De Vincenzo, F.
    Procopio, G.
    [J]. BJU INTERNATIONAL, 2012, 110 : 5 - 5
  • [5] Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Halabi, S.
    Rini, B. I.
    Stadler, W. M.
    Small, E. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Castro, Daniela
    Tripathi, Nishita
    Sayegh, Nicolas
    Gebrael, Georges
    Li, Xiaochen
    Meza, Luis
    Zengin, Zeynep
    Chehrazi-Raffle, Alex
    Govindarajan, Ameish
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Chawla, Neal
    Mercier, Benjamin
    Hsu, Joann
    Shi, Jessica
    Philip, Errol
    Bergerot, Cristiane
    Barragan-Carrillo, Regina
    Pal, Sumanta
    [J]. ONCOLOGIST, 2023, 28 : S5 - +
  • [7] PROGRESSION-FREE SURVIVAL (PFS) MODELING OF FIRST-LINE METASTATIC RENAL CELL CARCINOMA (1L MRCC) USING TUMOR GROWTH INHIBITION (TGI) METRICS.
    Li, J.
    Lin, S.
    Shahin, M.
    Nickens, D.
    Ouellet, D.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S71 - S71
  • [8] Use of early tumor shrinkage as a response to VEGF inhibitors as a predictor of progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Gruenwald, Viktor
    Seidel, Christoph
    Fenner, Martin
    Woike, Michael
    Kalanovic, Daniel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Early onset hypothyroidism as a predictor for progression-free survival (PFS) and overall survival (OS) benefit in patients with advanced renal cell carcinoma treated with first-line sunitinib
    Pinto, Alvaro
    Garrido, Maria
    Cruz, Patricia
    Lopez, David
    Zambrana, Francisco
    Aguayo, Cristina
    Fellu, Jaime
    Espinosa, Enrique
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
    Lemelin, Audreylie
    Ernst, Matthew Scott
    Wells, Connor
    Navani, Vishal
    McGregor, Bradley Alexander
    Wong, Shirley S.
    Pal, Sumanta Monty
    Basappa, Naveen S.
    Kapoor, Anil
    Lee, Jae-Lyun
    Donskov, Frede
    Li, Haoran
    Yuasa, Takeshi
    Chang, Rose
    Huynh, Lynn
    Nguyen, Catherine
    Holub, Ashley
    Clear, Louise
    Duh, Mei Sheng
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345